4.8 Article

SPOP mutation leads to genomic instability in prostate cancer

期刊

ELIFE
卷 4, 期 -, 页码 -

出版社

ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.09207

关键词

-

类别

资金

  1. National Cancer Institute (NCI) [2R01CA125612-05A1, K08CA187417-01]
  2. Prostate Cancer Foundation (PCF)
  3. Urology Care Foundation (Urology Care Foundation, Inc.)
  4. New York Community Trust (NYCT) The Frederick J. and Theresa Dow Wallace Fund
  5. European Research Council (ERC)
  6. Prostate Cancer UK [PG13-036]
  7. Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG13562]
  8. Prostate Cancer Foundation (PCF) Young Investigator Award
  9. Prostate Cancer UK [PG13-036] Funding Source: researchfish

向作者/读者索取更多资源

Genomic instability is a fundamental feature of human cancer often resulting from impaired genome maintenance. In prostate cancer, structural genomic rearrangements are a common mechanism driving tumorigenesis. However, somatic alterations predisposing to chromosomal rearrangements in prostate cancer remain largely undefined. Here, we show that SPOP, the most commonly mutated gene in primary prostate cancer modulates DNA double strand break (DSB) repair, and that SPOP mutation is associated with genomic instability. In vivo, SPOP mutation results in a transcriptional response consistent with BRCA1 inactivation resulting in impaired homology-directed repair (HDR) of DSB. Furthermore, we found that SPOP mutation sensitizes to DNA damaging therapeutic agents such as PARP inhibitors. These results implicate SPOP as a novel participant in DSB repair, suggest that SPOP mutation drives prostate tumorigenesis in part through genomic instability, and indicate that mutant SPOP may increase response to DNA-damaging therapeutics. DOI: 10.7554/eLife.09207.001

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据